CSPG4 and melanoma: Immunomagnetic capture of UM CTCs by targeting the melanoma-associated chondroitin sulphate proteoglycan (MCSP (also known as CSPG4, NG2)) protein was shown to successfully detect CTCs in patients with primary disease.